Prevention of Thromboembolic Events in Total Knee Replacement Patients

Inclusion Criteria: * Scheduled to undergo elective unilateral total knee arthroplayts (TKA) * Willing to comply with study requirements including bilateral venography at Day 12 ± 2 days * Body weight between 50 kg and 130 kg inclusive. * Normal aPTT, PT, INR at screening Exclusion Criteria: History of arterial or venous thromboembolism; abnormally extended primary or secondary bleeding after trauma or intervention, stroke, transient ischemic attack or traumatic or non-traumatic intracranial bleed; bleeding disorder; MI or unstable angina pectoris within 12 months of the screening; Uncontrolled hypertension (SBP/DBP ≥ 150/95 mmHg at the screening). Medications that increase the risk of bleeding, including antiplatelet (such as aspirin), anticoagulant and fibrinolytic agents; eGFR \< 60 mL/min/1.73m2; Poorly controlled diabetes (HbA1C \>10%); Liver dysfunction (ALT/AST \>3 xULN or TBL \>2 x ULN); BMI ≥ 40 kg/m2